The innovative technology behind
protexam– clinical proteome analysis – makes the test unique.
The clinical proteomic analysis was developed in over 20 years of clinical research.
Protexam Diagnostics is based on more than 20 years of continuous research in the field of clinical proteome analysis. This development originated from the work of mosaiques diagnostics GmbH, which, since 2002, has systematically established the analysis of proteins and peptides in human urine in collaboration with international university partners.
At the heart of the process lies the combination of capillary electrophoresis and mass spectrometry (CE-MS), which enables the high-resolution analysis of complex protein profiles. This methodology has been developed, standardised and applied in clinical trials over many years.
>100,000
_____________________________
samples and data sets
>450
_____________________________
scientific publications
>100
_____________________________
clinical trials
With the CE-MS technology developed and patented by
Prof. Dr. Dr. Harald Mischak, diseases can be diagnosed early and precisely. By comparing the proteome with the previously defined disease-specific protein patterns in the database, the individual state of health can be mapped.
The advantage for you lies in the detection of disease at a time when suitable therapy can still halt the damage to the organs. This is because the medicine of the future is an increasingly individualized medicine that is more strongly influenced by the idea of optimizing one's own body than by repairing temporary deficits.
Research into disease markers is usually based on an initial request from scientists at university hospitals. With each clinical study, new findings from proteome analysis are added to the creation and validation of new disease patterns. All data from the studies are fed into our database. Further studies are also planned for your benefit in the future.
Our strength is that we can compare each sample with the many data sets in our database. Each disease has its own disease-specific protein pattern. Each sample contains thousands of proteins and their fragments (peptides). We analyze these qualitatively and quantitatively with your sample. The high precision is not based on a single marker, but on a combination of hundreds of disease markers.
Some prominent scientists who were involved in the clinical studies on the basis of protexam:
Prof. Dr.
Antonia Vlahou
